Two Cases of Endometrial Adenocarcinoma Associated with Tamoxifen Use / 대한산부인과학회잡지

Tamoxifen citrate is a non-steroidal agent that has demonstrated estrogen agonist and antagonist properties and has found successful application for all stages, as adjuvant therapy, in the treatment of primary breast cancer. The drug was originally introduced for the treatment of high risk postmenopausal women or for postmenopausal patients with advanced disease. Since then, it was reported that long term treatment schedules could provide maximal benefit in preventing recurrences. Recent analyses of clinical trials have demonstrated an increase of disease-free survival in breast cancer among patients with positive estrogen receptor tumor. Tamoxifen is now recommended for chemoprevention of breast cancer in healthy high risk women. An agonist estrogenic effect upon the endometrium, the so called "paradoxical" effect, is suggested when proliferative changes, such as endometrial hyperplasia, adenocarcinoma, polyps. We report a case of endometrial cancer which developed in premenopausal patients with breast cancer under tamoxifen therapy.

Angiomyofibroblastoma Occupying Paravesical Space / 대한산부인과학회잡지

Angiomyofibroblastoma is a benign, distinctive, and rare soft tissue tumor of vulva and vagina that might be mistaken for aggressive angiomyxoma. It is suggested that angiomyofibroblastoma is slow-growing in nature and consistent with the benign clinical course reported in the literatures. 21-year-old woman complained of lower abdominal pain and odorous vaginal discharge. She had a large paravaginal mass obliterating vaginal canal. It was maybe absent 3 months ago, but it was occupied in paravesical space later. It revealed angiomyofibroblastoma, which rapid grew and located in vagina. It was removed by vaginal approach. This report describes a case of angiomyofibroblastoma in paravaginal space characterized by rapid growth.